This inventor holds 1 USPTO granted patent. Top assignee: Flow Pharma, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Scott Burkholtz and Controlled-Release Antibody Technology.
Introduction
Scott Burkholtz is an inventor associated with Redwood City, California, and Flow Pharma, Inc. His patent work concerns controlled delivery of an antibody for potential use in treating infections.
Latest Patents
Burkholtz is identified with 1 patent: “Controlled release of antibodies to modulate cytokines.” The patent describes an injectable formulation containing siltuximab encapsulated in poly(lactic-co-glycolic acid), or PLGA, microspheres. The microspheres are designed to release the antibody over hours, days, and weeks, with the release rate characterized by an absorption-rate constant. The disclosed applications include treating human patients with infections, including viral infections such as SARS-CoV.
Career Highlights
Burkholtz’s listed invention focuses on extending antibody delivery through a biocompatible polymer formulation. This approach is intended to provide controlled release of siltuximab rather than relying solely on immediate delivery.
Collaborations
His listed coworkers include Charles V. Herst and Tom Hodge. The invention is associated with Flow Pharma, Inc.
Conclusion
Scott Burkholtz’s patent centers on PLGA microspheres designed to provide controlled release of siltuximab, with potential applications in treating infections.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile